Two stocks in Healthcare
McKesson vs Thermo Fisher Scientific: profit, growth, debt and price compared
McKesson and Thermo Fisher Scientific are each stronger on 3 of 6 figures: McKesson on price for its expected profit, dividend and price trend; Thermo Fisher Scientific on profit margin, sales growth and analysts' view.
Save both stocks to your watchlist and revisit their latest fundamentals.
| McKessonMCK | Thermo Fisher ScientificTMO | |
|---|---|---|
| Net margin | 1.1% | Stronger: 14.9% |
| Revenue growth, past year | +7.57% | Stronger: +9.13% |
| Debt to equity | — | 75.4% |
| Forward P/E | Stronger: 20.7× | 24.9× |
| Dividend yield | Stronger: 0.31% | 0.27% |
| Analysts | Buy · 14 | Stronger: Strong buy · 25 |
| From its 200-day average | Stronger: +22.8% | +17.3% |
Share price over the past year
- McKesson+26.0%
- Thermo Fisher Scientific+20.3%
18 Nov 202518 Nov 2026
McKesson or Thermo Fisher Scientific: which is stronger?
- TMO
Which is more profitable?
Thermo Fisher Scientific keeps more of each sale as profit: 14.9% against 1.1%.
- TMO
Which is growing its sales faster?
Thermo Fisher Scientific is growing its sales faster: +9.13% over the past year, against +7.57%.
- MCK
Which costs less for the profit it is expected to make?
McKesson costs less for the profit it is expected to make: 20.7× its forward earnings, against 24.9×.
- MCK
Which pays more in dividends?
McKesson pays more back in dividends for what a share costs: 0.31% a year, against 0.27%.
- TMO
Which do analysts rate higher?
Analysts are warmer on Thermo Fisher Scientific: Strong buy, against Buy for McKesson.
- MCK
Which is in the stronger price trend?
McKesson's price is in the stronger trend: 22.8% above its 200-day average, against 17.3% above.
What each company does
MCKMcKesson
McKesson Corporation provides healthcare services in the United States and internationally.
Reports results on 3 February 2027
TMOThermo Fisher Scientific
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally.
Reports results on 28 January 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.